Share Twitter LinkedIn Facebook Email Sara M. Tolaney, MD, MPH, talks about whether the results of the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients are practice changing at Annual Meeting 2018.
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer Breast 4 Mins Read